GC
PMC

Globeflex Capital’s PharMerica Corporation PMC Stock Holding History

Globeflex Capital’s Portfolio PMC Stock Details PMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,317
Closed -$218K – 441
2017
Q2 		$218K Buy
+8,317
New +$204K 0.05% 310

Other funds holding PMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Globeflex Capital's PMC Position: Q3 2017 in Review

Globeflex Capital sold out of PharMerica Corporation (PMC) in Q3 2017, closing a stake of 8,317 shares — an estimated $218K sold.

Globeflex Capital first reported a position in PMC in Q2 2017 and held it in 1 quarter. The position peaked at $218K in Q2 2017. 150 funds tracked by Wall St. Rank hold PMC as of Q3 2017.

  • Globeflex Capital reported no remaining PharMerica Corporation position as of Q3 2017 after selling out during the quarter.
  • Globeflex Capital sold 8,317 PharMerica Corporation shares in Q3 2017, an estimated $218K.
  • Globeflex Capital first reported a position in PharMerica Corporation in Q2 2017 and held it in 1 quarter.
  • Globeflex Capital's PharMerica Corporation position peaked at $218K in Q2 2017.
  • 150 funds tracked by Wall St. Rank held PharMerica Corporation as of Q3 2017.

Based on Globeflex Capital's 13F filing for Q3 2017, filed 13 Nov 2017.